Episode Details

Harold Bernstein, Maze Therapeutics C-suite executive, cashed in on stock options, selling shares for $736,000, following a pre-set trading plan. The biotech firm, focusing on kidney, heart, and metabolic diseases, recently reported positive phase two trial data for its APOL1-related kidney drug candidate. Despite the promising results, shares dropped 33% due to broader biotech market swings. Maze Therapeutics plans to advance its drugs into larger pivotal trials, maintaining its long-term strategy.

Support the show:
Get a discount at https://solipillow.com/discount/dnn.

Advertise on DNN:
advertise@thednn.ai

This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.

View sources & latest updates:
https://sources.thednn.ai/521c2b94256dca1a